Search results
ClearSign Technologies Corporation Provides First Quarter 2024 Update
FOX 5 San Diego· 2 days agoClearSign Technologies Corporation (Nasdaq: CLIR) ("ClearSign" or the "Company"), an emerging leader in industrial combustion and sensing technologies that improve energy, operational efficiency ...
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024...
Benzinga· 5 days ago"The latest data from our preclinical study demonstrates KRRO-110 has the potential to restore AAT protein levels well beyond the minimum threshold considered to have an impact for patients, ...
Gold Terra's Drill Hole Approaching the Prolific Campbell Shear with Current Downhole Depth at 2,265...
Morningstar· 3 days agoVANCOUVER, BC / ACCESSWIRE / May 22, 2024 / Gold Terra Resource Corp. (TSXV:YGT);(Frankfurt:TX0);(OTCQX:YGTFF) (" Gold Terra " or the " Company ") is pleased to announce that drill hole GTCM24 ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoToday Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora ...
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at...
WKRN Nashville· 2 days agoIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) at ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 days agoKronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoCTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with ...
